325 related articles for article (PubMed ID: 25814008)
1. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
2. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
3. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
[TBL] [Abstract][Full Text] [Related]
4. Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.
Kurokawa M; Watanabe Nemoto M; Harada R; Kobayashi H; Horikoshi T; Kanazawa A; Togasaki G; Abe Y; Chazono H; Hanazawa T; Okamoto Y; Uno T
J Radiat Res; 2015 Sep; 56(5):849-55. PubMed ID: 26160181
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
[TBL] [Abstract][Full Text] [Related]
6. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
8. Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Ota Y; Kodaira T; Fujii H; Shimokawa M; Yokota T; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
Int J Clin Oncol; 2022 Nov; 27(11):1675-1683. PubMed ID: 36001247
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.
Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M
Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736
[TBL] [Abstract][Full Text] [Related]
10. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
11. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.
Huang J; Zhang J; Shi C; Liu L; Wei Y
BMC Cancer; 2016 Aug; 16(1):689. PubMed ID: 27565887
[TBL] [Abstract][Full Text] [Related]
12. [The Combination of Molecular Targeted Agents with Radiotherapy in Head and Neck Cancer].
Furuta M; Yokota T
Gan To Kagaku Ryoho; 2018 Mar; 45(3):419-423. PubMed ID: 29650896
[TBL] [Abstract][Full Text] [Related]
13. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.
Levy A; De Felice F; Bellefqih S; Guigay J; Deutsch E; Nguyen F; Blanchard P; Tao Y
Head Neck; 2016 Apr; 38 Suppl 1():E905-10. PubMed ID: 25974356
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
17. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
[TBL] [Abstract][Full Text] [Related]
18. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
[TBL] [Abstract][Full Text] [Related]
19. Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study.
Rudžianskas V; Inčiūra A; Vaitkus S; Padervinskis E; Rudžianskienė M; Kupčinskaitė-Noreikienė R; Saltonaitė L; Noreika A; Statnickaitė A; Juozaitytė E
Medicina (Kaunas); 2014; 50(2):92-9. PubMed ID: 25172603
[TBL] [Abstract][Full Text] [Related]
20. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
